Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ephedra Supplement Restriction Appropriate Under DSHEA? -Hatch to Henney

This article was originally published in The Tan Sheet

Executive Summary

FDA Commissioner-nominee Jane Henney, MD, is asked to provide her views on the agency's use of adverse events data on ephedra-containing dietary supplements as a primary basis for proposed restrictions on such products in an Oct. 1 letter from Sen. Orrin Hatch (R-Utah).

You may also be interested in...



Andro Bill Driven By National Media Coverage, Biden Says

Attention from ESPN and other national media has been a primary impetus behind growing support for legislation that would make androstenedione and other steroid precursors controlled substances

Andro Bill Driven By National Media Coverage, Biden Says

Attention from ESPN and other national media has been a primary impetus behind growing support for legislation that would make androstenedione and other steroid precursors controlled substances

Andro Bill Driven By National Media Coverage, Biden Says

Attention from ESPN and other national media has been a primary impetus behind growing support for legislation that would make androstenedione and other steroid precursors controlled substances

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088918

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel